• Cerebrovascular Consequences of Atherosclerosis

    Cerebrovascular Consequences of Atherosclerosis

    Atherosclerosis is not a disease that happens in isolation and can often lead to Small Vessel Disease and other serious end organ effects. Dr. Sandra Black discusses in detail many of the consequences of atherosclerosis on brain, including overt stroke, covert strokes and other small vessel pathologies. Through the CAIN program, Dr. Black is using various MR imaging sequences to fully understand these effects.  Read More
  • Translation to Clinical Research/Practice (CAIN3)

    Translation to Clinical Research/Practice (CAIN3)

    While imaging is recognized as a useful tool to characterize atherosclerosis and its complications, there is a critical need to undertake large population studies to truly understand the natural history of the disease as well as the links between imaging biomarkers and patient outcomes.  This presentation outlines the objectives of CAIN3, which are to compare the extent of atherosclerosis, and rate of atherosclerosis progression in different vascular beds and to determine the correlation between imaging biomarkers and cardiovascular outcomes.  Read More
  • Regulatory Perspective on Biomarkers and Surrogate Endpoints

    Regulatory Perspective on Biomarkers and Surrogate Endpoints

    As the Director of the Evaluation of Radiopharmaceuticals and Biotherapeutic Products at Health Canada, Dr. Klein gives a brief background on the introduction of the Food and Drug Act in Canada, followed by a full explanation of the regulatory process for biomarkers in Canada. The regulatory body focuses on the quality, safety and efficacy of diagnostic, preventative and therapeutic agents, being constantly evaluated from first discovery through market use to further evolution and all steps between.     Read More
  • 1
  • 2
  • 3
  • Regulatory Perspective on Biomarkers and Surrogate Endpoints +

    Regulatory Perspective on Biomarkers and Surrogate Endpoints As the Director of the Evaluation of Radiopharmaceuticals and Biotherapeutic Products at Health Canada, Dr. Klein gives a brief background Read More
  • Translation to Clinical Research/Practice (CAIN3) +

    Translation to Clinical Research/Practice (CAIN3) While imaging is recognized as a useful tool to characterize atherosclerosis and its complications, there is a critical need to Read More
  • Imaging Biomarkers in Vascular Cognitive Impairment +

    Imaging Biomarkers in Vascular Cognitive Impairment Using imaging to help unravel the complex relationships between vascular disease and cognitive impairment is the outline for this presentation. Read More
  • Myocardial Perfusion Imaging and Flow Quantification with Rubidium-82 PET +

    Myocardial Perfusion Imaging and Flow Quantification with Rubidium-82 PET Responding to the impending shut down of reactor facilities and a call for further research, deKemp et al. are exploring Read More
  • Translational Development of Novel Ligands for Cardiac and Renal Diseases +

    Translational Development of Novel Ligands for Cardiac and Renal Diseases The Ottawa Heart Institute is active in the development of novel radiopharmaceutical agents for PET imaging of cardiac diseases. Dr. Read More
  • 1
  • 2